The understanding of prostate cancer has significantly evolved in the past 15 years. Therefore, many people — including primary care providers — may not be aware of the current guidelines for prostate ...

Extended follow-up data from the ProtecT trial highlight the importance of weighing the risks associated with radical treatment versus active surveillance for newly diagnosed localized prostate cancer ...

Prostate-cancer screening based on prostate-specific antigen (PSA) levels in the blood was introduced—and readily adopted—in the United States around the late 1980s. But this screening method, in ...

A single round of prostate cancer screening that included a prostate-specific antigen (PSA) test, a kallikrein panel, and an MRI detected one additional high-grade cancer per 196 men and one low-grade ...

Credit: Getty Images In men with a total PSA of 2 ng/mL or more, a low percent-free PSA value is associated with a greater likelihood of clinically significant prostate cancer. Adding percent-free PSA ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on disease progression. Among patients with intermediate-risk prostate cancer, ...

For decades, it has been known that prostate specific antigen ‒ or PSA ‒ tests are a flawed way to diagnose prostate cancer. Many men have a high PSA without having cancer. Others have low PSA that ...

Prostate cancer is much more likely to kill if a man’s PSA level rises rapidly before the cancer is even diagnosed, according to a study that suggests a new and far more meaningful way of looking at ...

Clinical Trials—Real-World Data to Build a Future for Our Patients In the article that accompanies this editorial, Kwak et al 6 demonstrate using individual patient data from randomized trials that ...